Related Experiment Video

Updated: May 14, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes

Wilbert S Aronow1

  • 1Cardiology Division, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. wsaronow@aol.com

Postgraduate Medicine
|February 9, 2013
PubMed

Insights

Patients with acute coronary syndromes should receive dual antiplatelet therapy using aspirin plus clopidogrel, prasugrel, or ticagrelor. Specific patient histories and risk factors dictate drug choice and dosage to optimize treatment and minimize bleeding risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Acute coronary syndromes (ACS), including unstable angina pectoris and non-ST-segment elevation myocardial infarction, represent a critical cardiovascular emergency.
  • Effective management of ACS relies on prompt and appropriate antiplatelet therapy to prevent thrombotic events.

Purpose of the Study:

  • To outline current evidence-based recommendations for dual antiplatelet therapy (DAPT) in patients with ACS.
  • To define contraindications and specific considerations for using different P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in ACS management.
  • To clarify the role and limitations of glycoprotein IIb/IIIa inhibitors and newer agents like cangrelor and vorapaxar in ACS treatment.

Main Methods:

  • Review of clinical trial data and established guidelines for antiplatelet therapy in ACS.
  • Analysis of patient subgroups and specific clinical circumstances influencing treatment decisions.
  • Evaluation of safety profiles and efficacy data for various antiplatelet agents.

Main Results:

  • DAPT with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is the standard of care for ACS.
  • Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack.
  • Ticagrelor use requires limiting aspirin dosage to ≤100 mg daily.
  • Glycoprotein IIb/IIIa inhibitors are not recommended for triple antiplatelet therapy in non-high-risk bleeding patients.
  • Evidence does not support the use of cangrelor or vorapaxar in routine ACS management.

Conclusions:

  • Optimal antiplatelet strategy in ACS requires careful selection of agents based on individual patient characteristics, including bleeding risk and prior medical history.
  • Adherence to recommended dosages and contraindications is crucial for maximizing therapeutic benefit and minimizing adverse events.
  • Current evidence does not support the widespread use of newer agents like cangrelor and vorapaxar in the broad ACS population.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...